Market Cap 6.40B
Revenue (ttm) 130.13M
Net Income (ttm) -260.60M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -200.26%
Debt to Equity Ratio 0.00
Volume 768,400
Avg Vol 645,116
Day's Range N/A - N/A
Shares Out 66.74M
Stochastic %K 24%
Beta 2.12
Analysts Strong Sell
Price Target $126.38

Company Profile

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid r...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 264 4280
Fax: 857 264 4299
Address:
222 Berkeley Street, 12th Floor, Boston, United States
PrivateProfiteer
PrivateProfiteer Nov. 15 at 12:47 AM
$RYTM: The last close at $99.41 indicates a price below both the 30-day moving average (MA30) of $105.21 and the 50-day moving average (MA50) of $102.5, suggesting a bearish market context. The RSI at 33.06 indicates that the stock is oversold, which may signal a potential reversal or bounce. However, the stock is currently trading near the 60-day low of $94.39, which may provide support. Directional bias leans bearish due to the price being below key moving averages and the RSI indicating weakness. Suggested entry point: $95.00, aiming for a potential bounce. Stop loss: $93.00 to limit downside risk. Targets: $100.00 (first target) and $102.00 (second target) to capitalize on a possible recovery towards the MA50. Monitor for changes in momentum and volume as the trade progresses. https://privateprofiteers.com
0 · Reply
Quantumup
Quantumup Nov. 14 at 1:37 PM
Stifel reiterated $AARD Buy-$24 $SLNO $RYTM Stifel said: Most important to the stock, ARD-101's registrational ph3 HERO RCT in PWS remains on track with topline data anticipated in 3Q26. As outlined in our recent initiation (LINK), we continue to think there's an interesting risk/ reward into data with: (1) a ph2 clinical signal (looks similar to Vykat/beyond typical placebo); (2) an interesting biological/mechanistic story; and (3) a smart ph3 trial design that should help optimize the POS. Elsewhere, Aardvark continues to progress ARD-201 in obesity -- last week they presented interesting/supportive preclinical data across multiple relevant/predictive animal models (LINK). Initial ph2 POWER weight-maintenance data are expected 2H26 where, with no credit today (and significant investor/strategic interest in the space), we think there's interesting optionality for the stock. We also just hosted Aardvark at our healthcare conference, where we discussed ARD-101 and ARD-201 in much more detail.
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 14 at 4:21 AM
$RYTM: The last close at $95.89 indicates it's near the 60D low of $94.39, suggesting potential support. The RSI of 28.17 signals that the stock is oversold, which may lead to a reversal. However, the MA30 at $105.19 and MA50 at $102.55 indicate a bearish trend, as the price is significantly below these moving averages. Directional bias is bearish in the short term due to the MAs, but the oversold RSI may provide a countertrend opportunity. Suggested entry: $96.50, slightly above the last close to confirm upward momentum. Stop loss: $94.00, just below the 60D low to limit potential losses. Targets: First target at $100.00, aligning with psychological resistance, and a second target at $102.00, near the MA50. Monitor the market closely for any changes in momentum. https://privateprofiteers.com
0 · Reply
Stonky_Mcprofitface
Stonky_Mcprofitface Nov. 13 at 8:37 PM
When the stock was at $112, companies were knocking on $RYTM ‘s door holding bags of money ready to give them to whomever answered the door. But no one answered the door. We’re now in territory where this falls to $68, and they accept an offer for $90. A missed opportunity.
0 · Reply
abcdzepeda
abcdzepeda Nov. 13 at 8:25 PM
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 13 at 2:27 AM
$RYTM: The current market context indicates a bearish sentiment, as the last close at $99.86 is significantly below the 30-day moving average (MA30) of $105.31 and the 50-day moving average (MA50) of $102.8. The RSI at 34.9 suggests that the stock is approaching oversold conditions, but it is still below the typical threshold of 30, indicating potential for further downside before a reversal. Directional bias leans bearish due to the price being closer to the 60-day low of $93.64 compared to the high of $116.0. Suggested entry point is around $99.50, with a stop loss set at $95.00 to manage risk. Target 1 is $93.64 (60D low), and Target 2 is $90.00, allowing for potential downside movement. Monitor RSI for signs of reversal as it approaches oversold territory. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 12 at 2:03 AM
$RYTM: The current market context indicates a bearish sentiment, as the last close at $99.86 is significantly below the 30-day moving average (MA30) of $105.31 and the 50-day moving average (MA50) of $102.8. The RSI at 34.9 suggests that the stock is approaching oversold conditions, but it is still below the typical threshold of 30, indicating potential for further downside before a reversal. Directional bias leans bearish due to the price being closer to the 60-day low of $93.64 compared to the high of $116.0. Suggested entry point is around $99.50, with a stop loss set at $95.00 to manage risk. Target 1 is $93.64 (60D low), and Target 2 is $90.00, allowing for potential downside movement. Monitor RSI for signs of reversal as it approaches oversold territory. https://privateprofiteers.com
0 · Reply
judgeyoung2
judgeyoung2 Nov. 11 at 7:38 PM
$RYTM any thoughts on whether data will come this month or next month?
2 · Reply
Quantumup
Quantumup Nov. 11 at 2:04 PM
H.C. Wainwright reiterated $DRUG Buy/$85 $SLNO $RYTM $AARD LBPH - $HLUBF/ HLBBF H.C. Wainwright said in its note:
0 · Reply
JarvisFlow
JarvisFlow Nov. 10 at 8:36 PM
Canaccord Genuity has updated their rating for Rhythm Pharmaceuticals ( $RYTM ) to Buy with a price target of 114.
0 · Reply
Latest News on RYTM
Rhythm Pharmaceuticals, Inc. - Special Call

Sep 24, 2025, 5:07 PM EDT - 7 weeks ago

Rhythm Pharmaceuticals, Inc. - Special Call


Rhythm Pharmaceuticals: Buying This Rare Genetic Obesity Maven

Feb 25, 2025, 11:21 AM EST - 9 months ago

Rhythm Pharmaceuticals: Buying This Rare Genetic Obesity Maven


PrivateProfiteer
PrivateProfiteer Nov. 15 at 12:47 AM
$RYTM: The last close at $99.41 indicates a price below both the 30-day moving average (MA30) of $105.21 and the 50-day moving average (MA50) of $102.5, suggesting a bearish market context. The RSI at 33.06 indicates that the stock is oversold, which may signal a potential reversal or bounce. However, the stock is currently trading near the 60-day low of $94.39, which may provide support. Directional bias leans bearish due to the price being below key moving averages and the RSI indicating weakness. Suggested entry point: $95.00, aiming for a potential bounce. Stop loss: $93.00 to limit downside risk. Targets: $100.00 (first target) and $102.00 (second target) to capitalize on a possible recovery towards the MA50. Monitor for changes in momentum and volume as the trade progresses. https://privateprofiteers.com
0 · Reply
Quantumup
Quantumup Nov. 14 at 1:37 PM
Stifel reiterated $AARD Buy-$24 $SLNO $RYTM Stifel said: Most important to the stock, ARD-101's registrational ph3 HERO RCT in PWS remains on track with topline data anticipated in 3Q26. As outlined in our recent initiation (LINK), we continue to think there's an interesting risk/ reward into data with: (1) a ph2 clinical signal (looks similar to Vykat/beyond typical placebo); (2) an interesting biological/mechanistic story; and (3) a smart ph3 trial design that should help optimize the POS. Elsewhere, Aardvark continues to progress ARD-201 in obesity -- last week they presented interesting/supportive preclinical data across multiple relevant/predictive animal models (LINK). Initial ph2 POWER weight-maintenance data are expected 2H26 where, with no credit today (and significant investor/strategic interest in the space), we think there's interesting optionality for the stock. We also just hosted Aardvark at our healthcare conference, where we discussed ARD-101 and ARD-201 in much more detail.
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 14 at 4:21 AM
$RYTM: The last close at $95.89 indicates it's near the 60D low of $94.39, suggesting potential support. The RSI of 28.17 signals that the stock is oversold, which may lead to a reversal. However, the MA30 at $105.19 and MA50 at $102.55 indicate a bearish trend, as the price is significantly below these moving averages. Directional bias is bearish in the short term due to the MAs, but the oversold RSI may provide a countertrend opportunity. Suggested entry: $96.50, slightly above the last close to confirm upward momentum. Stop loss: $94.00, just below the 60D low to limit potential losses. Targets: First target at $100.00, aligning with psychological resistance, and a second target at $102.00, near the MA50. Monitor the market closely for any changes in momentum. https://privateprofiteers.com
0 · Reply
Stonky_Mcprofitface
Stonky_Mcprofitface Nov. 13 at 8:37 PM
When the stock was at $112, companies were knocking on $RYTM ‘s door holding bags of money ready to give them to whomever answered the door. But no one answered the door. We’re now in territory where this falls to $68, and they accept an offer for $90. A missed opportunity.
0 · Reply
abcdzepeda
abcdzepeda Nov. 13 at 8:25 PM
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 13 at 2:27 AM
$RYTM: The current market context indicates a bearish sentiment, as the last close at $99.86 is significantly below the 30-day moving average (MA30) of $105.31 and the 50-day moving average (MA50) of $102.8. The RSI at 34.9 suggests that the stock is approaching oversold conditions, but it is still below the typical threshold of 30, indicating potential for further downside before a reversal. Directional bias leans bearish due to the price being closer to the 60-day low of $93.64 compared to the high of $116.0. Suggested entry point is around $99.50, with a stop loss set at $95.00 to manage risk. Target 1 is $93.64 (60D low), and Target 2 is $90.00, allowing for potential downside movement. Monitor RSI for signs of reversal as it approaches oversold territory. https://privateprofiteers.com
0 · Reply
PrivateProfiteer
PrivateProfiteer Nov. 12 at 2:03 AM
$RYTM: The current market context indicates a bearish sentiment, as the last close at $99.86 is significantly below the 30-day moving average (MA30) of $105.31 and the 50-day moving average (MA50) of $102.8. The RSI at 34.9 suggests that the stock is approaching oversold conditions, but it is still below the typical threshold of 30, indicating potential for further downside before a reversal. Directional bias leans bearish due to the price being closer to the 60-day low of $93.64 compared to the high of $116.0. Suggested entry point is around $99.50, with a stop loss set at $95.00 to manage risk. Target 1 is $93.64 (60D low), and Target 2 is $90.00, allowing for potential downside movement. Monitor RSI for signs of reversal as it approaches oversold territory. https://privateprofiteers.com
0 · Reply
judgeyoung2
judgeyoung2 Nov. 11 at 7:38 PM
$RYTM any thoughts on whether data will come this month or next month?
2 · Reply
Quantumup
Quantumup Nov. 11 at 2:04 PM
H.C. Wainwright reiterated $DRUG Buy/$85 $SLNO $RYTM $AARD LBPH - $HLUBF/ HLBBF H.C. Wainwright said in its note:
0 · Reply
JarvisFlow
JarvisFlow Nov. 10 at 8:36 PM
Canaccord Genuity has updated their rating for Rhythm Pharmaceuticals ( $RYTM ) to Buy with a price target of 114.
0 · Reply
FE123
FE123 Nov. 9 at 12:29 AM
$RYTM 105% ownership! Went from $10 to over $100! $TENX Currently at 106% Ownership and $7 Positive Phase 3 Results Should take us over $100
0 · Reply
abcdzepeda
abcdzepeda Nov. 7 at 10:33 PM
$RYTM I guess the bat signal worked, as we closed green for the first time in a week of being in a sea of red! 😂😂😂😂
0 · Reply
JarvisFlow
JarvisFlow Nov. 7 at 7:45 PM
Needham has updated their rating for Rhythm Pharmaceuticals ( $RYTM ) to Buy with a price target of 120.
0 · Reply
Quantumup
Quantumup Nov. 7 at 7:24 PM
Goldman Sachs trimmed⬇️ $RYTM's PT to $141 from $142/keeps at a Buy rating. $LLY $SLNO $AARD Here's what Goldman Sachs had to say:
0 · Reply
Stonky_Mcprofitface
Stonky_Mcprofitface Nov. 7 at 5:32 PM
$RYTM The CEO sounded like a man who’s just had his net worth decline by more than 10%.
1 · Reply
abcdzepeda
abcdzepeda Nov. 7 at 4:21 PM
$RYTM
0 · Reply
topstockalerts
topstockalerts Nov. 7 at 3:24 PM
Rhythm Pharmaceuticals Inc. shares dropped on Friday after the company announced that the U.S. Food and Drug Administration has extended its review period for IMCIVREE® (setmelanotide) by three months. The FDA notified Rhythm on November 6 that the Prescription Drug User Fee Act target date for the Supplemental New Drug Application has been pushed from December 20, 2025, to March 20, 2026. The delay follows a request from the FDA for additional sensitivity analyses of the company’s Phase 3 pivotal clinical trial data on hypothalamic obesity, which was submitted in October. Rhythm clarified that no new data was required, and the additional information was considered a "major amendment," giving the FDA more time for review. The amendment did not include any new safety or manufacturing data for setmelanotide. The company is seeking FDA approval for IMCIVREE to treat acquired hypothalamic obesity, a condition with no current FDA-approved treatments. $RYTM
0 · Reply
notreload_ai
notreload_ai Nov. 7 at 1:53 PM
$RYTM announced that the FDA has extended the review of its obesity drug Imcivree for acquired hypothalamic obesity by three months, moving the decision date to March 20, 2026. https://notreload.xyz/fda-delays-rhythm-imcivree-review-for-rare-obesity-drug/
0 · Reply
TwongStocks
TwongStocks Nov. 7 at 12:32 PM
$RYTM Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity https://ir.rhythmtx.com/news-releases/news-release-details/rhythm-pharmaceuticals-announces-fda-extension-review-period-0 On Nov. 6, the FDA notified the Company that the Prescription Drug User Fee Act (PDUFA) goal date has been extended from December 20, 2025 to March 20, 2026.
0 · Reply
Quantumup
Quantumup Nov. 7 at 12:11 PM
BTIG🏁 $AARD at a Buy rating and a $26 PT. $SLNO $RYTM $LLY $NVO VKTX BTIG in its initiation report said: Aardvark Therapeutics is a clinical stage biopharmaceutical company developing ARD-101, a TAS2R agonist for Prader Willi Syndrome (PWS), and ARD-201 for weight loss and weight rebound prevention. The ph 3 HERO trial of ARD-101 is ongoing in PWS patients, with topline data expected in 3Q26. We expect data from the phase 2 POWER (weight maintenance) trial in 2H26 and start of the STRENGTH trial (weight loss) in 1H26. We believe '101's excellent safety profile and differentiated mechanism are underappreciated by the Street, but the real upside comes from '201 and the opportunity to prevent weight regain from GLP-1 discontinuations or to tack on additional weight loss on top of a GLP-1RA. We believe the current valuation, coupled with unmet needs in the PWS and obesity markets, provide a positive set up to shares over the next 12 mos. Initiate at Buy and $26PT.
0 · Reply
abcdzepeda
abcdzepeda Nov. 6 at 1:44 AM
$RYTM Rhythm Pharmaceuticals Announces Public Reimbursement for IMCIVREE® (setmelanotide) in Canada in Five Provinces and Under the Federal Non-Insured Health Benefits Program
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Nov. 5 at 9:35 PM
This is not investment advice. The attachment compares $SLNO valuation as a multiple of product revenues by quarter post launch to 5 peers. A few weeks ago, Seeking Alpha cited a Betaville Uncooked Alert that SLNO was in active M&A negotiations. We have not read the minutes of SLNO's Q3 2025 (Q2 post launch) conference call. $RYTM expects to report Phase 2 data in PWS by the end of the year & $AARD expects to reports its Phase 3 data in Q3 2026. $XBI $IBB
2 · Reply